Faldaprevir manufacturers
- Faldaprevir
-
- $1.00
-
2019-12-26
- CAS:801283-95-4
- Min. Order: 1g
- Purity: ≥98%
|
| | Faldaprevir Basic information |
| Product Name: | Faldaprevir | | Synonyms: | BI 201335;Faldaprevir;Faldaprevir(BI 201335);(1R,2S)-N-[(Cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-bromo-7-methoxy-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-cyclopropanecarboxylic acid;BI201335; BI 201335; BI-201335;Faldaprevir-d7;Cyclopropanecarboxylic acid, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-bromo-7-methoxy-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-, (1R,2S)-;(1R,2S)-1-((2S,4R)-4-((8-Bromo-2-(2-isobutyramidothiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxamido)-2-vinylcyclopropane-1-carboxylic acid | | CAS: | 801283-95-4 | | MF: | C40H49BrN6O9S | | MW: | 869.82 | | EINECS: | | | Product Categories: | | | Mol File: | 801283-95-4.mol |  |
| | Faldaprevir Chemical Properties |
| Melting point | 235 °C | | density | 1.465±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | solubility | DMSO:0.0(Max Conc. mg/mL);0.0(Max Conc. mM) | | pka | 4.736±0.50(predicted) | | form | Solid | | color | White to off-white |
| | Faldaprevir Usage And Synthesis |
| Uses | Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection[1][2]. | | References | [1] Llinàs-Brunet M, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem. 2010 Sep 9;53(17):6466-76. DOI:10.1021/jm100690x
[2] Zeuzem S, et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther. 2013;18(8):1015-9. DOI:10.3851/IMP2567 |
| | Faldaprevir Preparation Products And Raw materials |
|